



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Salvatore AVOLIO et al.	Art Unit: 1624
Serial No.:	10/500,971	Examiner: Deepak R. RAO
Filed:	February 16, 2005	Case No.: ITT0039YP USA
For:	PYRIMIDINONE VIRAL POLYMERASE INHIBITORS	

DECLARATION UNDER 37 C.F.R. §1.132

I, Michael Rowley, a citizen of the United Kingdom, hereby declare and state:

1. I have a doctoral degree in Natural Sciences, which was conferred upon me by the Faculty of the University of Cambridge in Cambridge, England, in 1986. My thesis was entitled "Some Uses of Tin Compounds in Organic Synthesis."
2. I was a post-doctoral research fellow at Harvard University from 1986 to 1988, and concentrated my research during this period on the total synthesis of Ophiobolin C, under the direction of Professor Yoshito Kishi.
3. I have been employed by Merck & Co., Inc., or subsidiaries thereof, since September of 1988, and I have had a total of 27 years of work and research experience in organic synthesis and the development and synthesis of pharmaceutically active agents.
4. I am an active member of the Royal Society of Chemistry, the Italian Chemical Society and the American Chemical Society.


5. A representative listing of publications of which I am an author is provided as Annex A to this Declaration.

6. A representative listing of patents and published patent applications on which I am a named inventor is provided as Annex B to this Declaration.

7. I have reviewed the above-captioned patent application and the currently pending claims, as well as the proposed claim amendments.

8. I have reviewed the outstanding Final Rejection, particularly the rejection of claims 1, 3-9, 11, 13 and 14 under 35 U.S.C. §103(a) over International Patent Application Publication No. WO 02/006246 to Gardelli et al. I have also reviewed the Gardelli reference.

9. The '246 publication teaches 2-aryl-4,5-dihydroxy-6-carboxypyrimidines of formula I that exist in equilibrium with tautomeric forms such as those of formula IA. See '246 publication, page 1, line 25 – page 2, line 12.



10. The cited '246 publication teaches that compounds of its formula I are tautomeric; that is, the compounds of the '246 publication undergo tautomeric rearrangements in which hydrogen from a ring enol moves to the adjacent nitrogen and

back. These tautomeric forms exist because the ring nitrogens are unsubstituted. Such chemical rearrangements are well understood in the arts relating to organic chemistry and chemical synthesis.

11. When the nitrogen has an alkyl substituent, as in R¹ of the claimed compounds, the compounds cease to exist as tautomers. That is, the tautomeric rearrangement is no longer possible; the "blockage" of tautomeric rearrangement by substitution is also well known.



12. The '246 publication does not suggest blocking tautomerization by providing an alkyl substituent on the ring nitrogen, as in the pending claims. Rather, the '246 publication specifically discloses compounds that form tautomers.

13. However, further research showed that alkyl substitutions of the ring nitrogen, as currently claimed, not only provide distinct compounds that do not undergo tautomeric rearrangements, but that have improved oral bioavailability. Such improved oral bioavailability over the tautomeric compounds disclosed and claimed in the '246 publication would not have been understood from the disclosures of the '246 publication, at least because there is no indication in the reference that blocking tautomerization would provide such improved compounds.



14. I and/or those under my direct supervision and control have prepared and tested several representative compounds according to the claims and corresponding tautomeric compounds. Comparative data for representative compounds is provided in the tables below and discussed in the following paragraphs. In the tables, the term "F(rat)%" refers to the percentage of compound that was found to be orally

bioavailable in rats, as determined by dosing the compound orally and intravenously to rats, measuring the concentration at various time points, and calculating the Area Under the concentration-time Curve (AUC). The oral bioavailability is defined as the ratio of the AUC when dosed orally to the AUC when dosed intravenously. The term " IC_{50} " refers to the concentration of the compound required to inhibit, in a biochemical reaction *in vitro*, fifty percent of the activity of the HCV NS5B RNA-dependent RNA polymerase activity.


15. Table 1

Compound	 (tautomeric)	
F(rat)%	6	25
IC_{50} (μ M)	2.5	4.7

16. Table 2

Compound	 (tautomeric)	
F(rat)%	1	12
IC_{50} (μ M)	0.16	1.2

17. In addition, the following compound was found to have an IC_{50} of 8.2 μ M and an F(rat)% oral bioavailability of 100%.




18. As can be seen from the compounds tested, tautomeric compounds such as those disclosed in the '246 publication do not provide the oral bioavailability achieved by the alkyl substituted compounds of the claims. To provide effective therapy for HCV, it is preferable to have compounds that are orally bioavailable, and thus, the compounds of the claims show potential, unexpected, advantage.

19. I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true, and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine and/or imprisonment under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application and/or of any patent issuing therefrom.

Date:

18 September 2007



Michael Rowley

Annex A: Representative Publications

1. Jones, P.; Altamura, S.; Chakravarty, P. K.; Cecchetti, O.; De Francesco, R.; Gallinari, P.; Ingenito, R.; Meinke, P. T.; Petrocchi, A.; Rowley, M.; Scarpelli, R.; Serafini, S.; Steinkuehler, C., *A series of novel, potent, and selective histone deacetylase inhibitors*, 16 BIOORG. MED. CHEM. LETT. 5948-52 (2006).
2. Summa, V.; Petrocchi, A.; Matassa, V. G.; Gardelli, C.; Muraglia, E.; Rowley, M.; Paz, O. G.; Laufer, R.; Monteagudo, E.; Pace, P., *4,5-Dihydroxypyrimidine Carboxamides and N-Alkyl-5-hydroxypyrimidinone Carboxamides Are Potent, Selective HIV Integrase Inhibitors with Good Pharmacokinetic Profiles in Preclinical Species*, 49 J. MED. CHEM. 6646-49 (2006).
3. Ontoria, J. M.; Martin Hernando, J. I.; Malancona, S.; Attenni, B.; Stansfield, I.; Conte, I.; Ercolani, C.; Habermann, J.; Ponzi, S.; Di Filippo, M.; Koch, U.; Rowley, M.; Narjes, F., *Identification of thieno[3,2-b]pyrroles as allosteric inhibitors of hepatitis C virus NS5B polymerase*, 16 BIOORG. MED. CHEM. LETT. 4026-30 (2006).
4. Muraglia, E.; Kinzel, O. D.; Laufer, R.; Miller, M. D.; Moyer, G.; Munshi, V.; Orvieto, F.; Palumbi, M. C.; Pescatore, G.; Rowley, M.; Williams, P. D.; Summa, V., *Tetrazole thioacetanilides: Potent non-nucleoside inhibitors of WT HIV reverse transcriptase and its K103N mutant*, 16 BIOORG. MED. CHEM. LETT. 2748-52 (2006).
5. Di Marco, S.; Volpari, C.; Tomei, L.; Altamura, S.; Harper, S.; Narjes, F.; Koch, U.; Rowley, M.; De Francesco, R.; Migliaccio, G.; Carfi, A., *Interdomain Communication in Hepatitis C Virus Polymerase Abolished by Small Molecule Inhibitors Bound to a Novel Allosteric Site*, 280 J. BIO. CHEM. 29765-70 (2005).
6. Harper, S.; Avolio, S.; Pacini, B.; Di Filippo, M.; Altamura, S.; Tomei, L.; Paonessa, G.; Di Marco, S.; Carfi, A.; Giuliano, C.; Padron, J.; Bonelli, F.; Migliaccio, G.; De Francesco, R.; Laufer, Ralph; Rowley, M.; Narjes, F., *Potent Inhibitors of Subgenomic Hepatitis C Virus RNA Replication through Optimization of Indole-N-Acetamide Allosteric Inhibitors of the Viral NS5B Polymerase*, 48 J. MED. CHEM. 4547-57 (2005).
7. Harper, S.; Pacini, B.; Avolio, S.; Di Filippo, M.; Migliaccio, G.; Laufer, R.; De Francesco, R.; Rowley, M.; Narjes, F., *Development and Preliminary Optimisation of Indole N-Acetamide Inhibitors of the HCV NS5B Polymerase*, 48 J. MED. CHEM. 1314-17 (2005).
8. Crawforth, J.; Atack, J. R.; Cook, S. M.; Gibson, K. R.; Nadin, A.; Owens, A. P.; Pike, A.; Rowley, M.; Smith, A. J.; Sohal, B.; Sternfeld, F.; Wafford, K.; Street, L. J., *Tricyclic pyridones as functionally selective human GABAA α 2/3 receptor-ion channel ligands*, 14 BIOORG. MED. CHEM. LETT. 1679-82 (2004).

9. Tomei, L.; Altamura, S.; Bartholomew, L.; Biroccio, A.; Ceccacci, A.; Pacini, L.; Narjes, F.; Gennari, N.; Bisbocci, M.; Incitti, I.; Orsatti, L.; Harper, S.; Stansfield, I.; Rowley, M.; De Francesco, R.; Migliaccio, G., *Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase*, 77 J. VIROLOGY 13225-31 (2003).
10. Gibson, K. R.; Hitzel, L.; Mortishire-Smith, R. J.; Gerhard, U.; Jelley, R. A.; Reeve, A. J.; Rowley, M.; Nadin, A.; Owens, A. P., *Synthesis and Conformational Dynamics of Tricyclic Pyridones Containing a Fused Seven-Membered Ring*, 67 J. ORG. CHEM. 9354-60 (2002).
11. Rowley, M., *Some aspects of heterocyclic chemistry in drug discovery. Seminars in Organic Synthesis*, 27th Summer School "A. Corbella", Gargnano, Italy (2002).
12. Collins, I.; Moyes, C.; Davey, W. B.; Rowley, M.; Bromidge, F. A.; Quirk, K.; Atack, J. R.; McKernan, R. M.; Thompson, S.-A.; Wafford, K.; Dawson, G. R.; Pike, A.; Sohal, B.; Tsou, N. N.; Ball, R. G.; Castro, J. L., *3-Heteroaryl-2-pyridones: Benzodiazepine Site Ligands with Functional Selectivity for $\alpha 2/\alpha 3$ -Subtypes of Human GABAA Receptor-Ion Channels*, 45 J. MED. CHEM. 1887-1900 (2002).
13. Gibson, K.R.; Thomas, S. R.; Rowley, M., *An intramolecular sulfoxide alkylation-elimination approach to the [1,2,3]triazolo[1,5-a]pyrimidine ring system*, (5) SYN. LETT. 712-714 (2001).
14. Rowley, M.; Hallett, D. J.; Goodacre, S.; Moyes, C.; Crawforth, J.; Sparey, T. J.; Patel, S.; Marwood, R.; Patel, S.; Thomas, S.; Hitzel, L.; O'Connor, D.; Szeto, N.; Castro, J. L.; Hutson, P.H.; MacLeod, A. M., *3-(4-Fluoropiperidin-3-yl)-2-phenylindoles as High Affinity, Selective and Orally Bioavailable h5HT_{2A} Receptor Antagonists*, 44 J. MED. CHEM. 1603-14 (2001).
15. Rowley, M.; Bristow, L.; Hutson, P., *Perspective: Current and novel approaches to the drug treatment of schizophrenia*, 44 J. MED. CHEM. 477-501 (2001).
16. Crawforth, J.; Goodacre, S.; Maxey, R.; Bourrain, S.; Patel, S.; Marwood, R.; O'Connor, D.; Herbert, R.; Hutson, P.; Rowley, M., *3-(4-Piperidinyl)- and 3-(8-aza-bicyclo[3.2.1]oct-3-yl)-2-phenyl-1H-indoles as bioavailable h5-HT_{2A} antagonists*, ___ BIOORG. MED. CHEM. LETT. 2701-03 (2000).
17. Hallett, D. J.; Gerhard U.; Goodacre, S. C.; Hitzel, L.; Sparey, T. J.; Thomas, S.; Rowley M.; Ball R. G., *Neighboring group participation of the indole nucleus: an unusual DAST-mediated rearrangement reaction*, 65 J. ORG. CHEM. 4984 (2000).
18. Collins, I.; Davey, W. B.; Rowley, M.; Quirk, K.; Bromidge, F. A.; McKernan, R. M.; Thompson, S.-A.; Wafford, K. A., *N-(Indol-3-ylglyoxylyl)piperidines:*

high affinity agonists of human GABA-A receptors containing the $\alpha 1$ subunit, 10 BIOORG. MED. CHEM. LETT. 1381-84 (2000).

19. Ahmed, A.; Clayden, J.; Rowley, M., *1,3,4,5-Tetrahydroazepin-2-ones by dearomatising anionic cyclisation of N-allyl-1-naphthamides*, 12 SYN. LETT. 1954-56 (1999).

20. van Niel, M. B.; Collins, I.; Beer, M. S.; Broughton, H. B.; Cheng, S. K. F.; Goodacre, S. C.; Heald, A.; Locker, K. L.; MacLeod, A. M.; Morrison, D.; Moyes, C. R.; O'Connor, D.; Pike, A.; Rowley, M.; Russell, M. G. N.; Sohal, B.; Stanton, J. A.; Thomas, S.; Verrier, H.; Watt, A. P.; Castro, J. L., *Fluorination of 3-(3-(Piperidin-1-yl)propyl)indoles and 3-(3-(1-piperazinyl)propyl)indoles Gives Selective Human 5-HT_{1D} Receptor Ligands with Improved Pharmacokinetic Profiles*, 42 J. MED. CHEM. 2087-2104 (1999).

21. Moore, K. W.; Bonner, K.; Jones, E. A.; Emms, F.; Leeson, P. D.; Marwood, R.; Patel, S.; Patel, S.; Rowley, M.; Thomas, S.; Carling, R. W., *4-N-linked-heterocyclic piperidine derivatives with high affinity and selectivity for human dopamine D4 receptors*, __ BIOORG. MED. CHEM. LETT. 1285-90 (1999).

22. Ahmed, A.; Clayden, J.; Rowley, M., *Anion translocation in organolithiums: a mechanism for the lithiation and cyclization of tertiary naphthamides*, 39(34) TET. LETT. 6103-06 (1998).

23. Bourrain, S.; Collins, I.; Neduvélil, J. G.; Rowley, M.; Leeson, P. D.; Patel, S.; Patel, S.; Emms, F.; Marwood, R.; Chapman, K. L.; Fletcher, A. E.; Showell, G. A., *Substituted pyrazoles as novel selective ligands for the human dopamine D4 receptor*, 6 BIOORG. MED. CHEM. LETT. 1731-43 (1998).

24. Collins, I.; Rowley, M.; Davey, M. B.; Emms, F.; Marwood, R.; Patel, S.; Patel, S.; Fletcher, A.; Ragan, I. C.; Leeson, P. D.; Scott, A. L.; Broten, T., *3-(1-Piperazinyl-4,5-dihydro-1H-benzo[g]indazoles: high affinity ligands for the human dopamine D4 receptor with improved selectivity over ion channels*, 6 BIOORG. MED. CHEM. LETT. 1655 (1998).

25. Ahmed, A.; Clayden, J.; Rowley, M., *Anionic cyclizations of an N-benzyl naphthamide: a route to benz[e]isoindolones*, J. CHEM. SOC., CHEM. COMMUN., 297-298 (1998).

26. Rowley, M.; Kulagowski, J. J.; Watt, A. P.; Rathbone, D.; Stevenson, G. I.; Carling, R. W.; Baker, R.; Marshall, G. R.; Kemp, J. A.; Foster, A. C.; Grimwood, S.; Hargreaves, R.; Hurley, C.; Saywell, K. L.; Leeson, P. D., *The Effect of Plasma Protein Binding on In Vivo Activity and Brain Penetration in Glycine/NMDA Receptor Antagonists*, 40 J. MED. CHEM. 4053-68 (1997).

27. Rowley, M.; Collins, I.; Broughton, H.B.; Davey, W.B.; Baker, R.; Emms, F.; Marwood, R.; Patel, S.; Patel, S.; Ragan, C.I.; Freedman, S.B.; Ball R.,

Leeson, P.D., *4-Heterocyclylpiperidines as Selective High Affinity Ligands at the Human Dopamine D4 Receptor*, 40 J. MED. CHEM. 2374-85 (1997).

28. Pernia, G. J.; Kilburn, J. D.; Essex, J. W.; Mortishire-Smith, R. J.; Rowley, M., *Stabilization of a Cis Amide Bond in a Host-Guest Complex*, 118 J. AM. CHEM. SOC. 10220-27 (1996).

29. Curtis, N. R.; Kulagowski, J. J.; Leeson, P. D.; Mawer, I. M.; Ridgill, M. P.; Rowley, M.; Grimwood, S.; Marshall, G. R., *Synthesis and SAR of diiodotyrosine-derived glycine-site N-methyl-D-aspartate receptor ligands*, 6 BIOORG. MED. CHEM. LETT. 1145-50 (1996).

30. Rowley, M.; Broughton, H. B.; Collins, I.; Baker, R.; Emms, F.; Marwood, R.; Patel, S.; Patel, S.; Ragan, C.I.; Leeson P.D., *5-(4-Chlorophenyl)-4-methyl-3-(1-(2-phenylethyl)piperidin-4-yl)isoxazole: A Potent, Selective Antagonist at Human Cloned Dopamine D4 Receptors*, 39 J. MED. CHEM. 943-45 (1996).

31. Rowley, M.; Leeson, P.D.; Grimwood, S.; Marshall, G.; Saywell, K., *5,6,7,8-Tetrahydroquinolones as antagonists at the glycine site of the NMDA receptor*, 5 BIOORG. MED. CHEM. LETT. 2089-92 (1995).

32. Grimwood, S.; Kulagowski, J. J.; Mawer, I. M.; Rowley, M.; Leeson, P. D.; Foster, A. C., *Allosteric modulation of the glutamate site on the NMDA receptor by four novel glycine site antagonists*, 290 EUR. J. PHARMACOL., MOL. PHARMACOL. SECT. 221-26 (1995).

33. Pernia, G. J.; Kilburn, J. D.; Rowley, M., *A novel receptor for amino acid derivatives*, J. CHEM. SOC., CHEM. COMMUN. 305-6 (1995).

34. Tricklebank, M. D.; Bristow, L. J.; Hutson, P. H.; Leeson, P. D.; Rowley, M.; Saywell, K.; Singh, L.; Tattersall, F. D.; Thorn, L.; Williams, B. J., *The anticonvulsant and behavioral profile of L-687,414, a partial agonist acting at the glycine modulatory site on the N-methyl-D-aspartate (NMDA) receptor complex*. Br, 113 J. PHARMACOL. 729-36 (1994).

35. Kulagowski, J. J.; Baker, R.; Curtis, N. R.; Mawer, I. M.; Moseley, A. M.; Ridgill, M. P.; Rowley, M.; Stansfield, I.; Leeson, P. D., *3'-(Arylmethyl)- and 3'-(Aryloxy)-3-phenyl-4-hydroxyquinolin- 2(1H)-ones: Orally Active Antagonists of the Glycine Site on the NMDA Receptor*, 37 J. MED. CHEM. 1402-5 (1994).

36. Leeson, P.D.; Baker R.; Carling R.W.; Kulagowski J.J.; Mawer I.M.; Ridgill M.P.; Rowley M.; Smith J.A.; Stansfield I.; Stevenson G.I.; Foster A.C.; Kemp J.A., *Amino acid bioisosteres: Design of 2-quinolone derivatives as glycine-site N-methyl-D-Aspartate receptor antagonists*, 3 BIOORG. MED. CHEM. LETT. 299-304 (1993).

37. Rowley, M.; Leeson, P. D.; Stevenson, G. I.; Moseley, A. M.; Stansfield, I.; Sanderson, I.; Robinson, L.; Baker, R.; Kemp, J. A., *3-Acyl-4-hydroxyquinolin-2(1H)-ones. Systemically active anticonvulsants acting by antagonism at the glycine site of the N-methyl-D-aspartate receptor complex*, 36 J. MED. CHEM. 3386-96 (1993).
38. Leeson, P. D.; Carling, R. W.; Kulagowski, J. J.; Mawer, I. M.; Moore, K. W.; Moseley, A. M.; Rowley, M.; Smith, J. D.; Stevenson, G. I., *Drugs interacting with the glycine binding site*, PERSPECT. MED. CHEM. 239-57 (ed. Testa, Bernard, 1993).
39. Leeson, P.D.; Williams, B.J.; Rowley, M.; Moore, K.W.; Baker, R.; Kemp, J.A.; Priestley, T.; Foster, A.C.; Donald, A.E., *Derivatives of 1-hydroxy-3-aminopyrrolidin-2-one (HA966). Partial agonists at the glycine site of the NMDA receptor*, 3 BIOORG. MED. CHEM. LETT. 71-76 (1993).
40. Rowley, M.; Leeson, P.D.; Grimwood, S.; Foster, A.; Saywell, K., *2-carboxyindolines and indoles as potential glycine/NMDA antagonists: Effects of five membered ring conformation on affinity*, 2 BIOORG. MED. CHEM. LETT. 1627-30 (1992).
41. Rowley, M.; Leeson, P.D.; Williams, B.J.; Moore, K.W.; Baker R., *Routes to 4-substituted analogues of the glycine/NMDA antagonist HA-966. Enantioselective synthesis of (3R,4R) 3-Amino-1-Hydroxy-4-methyl-2-pyrrolidinone (L-687,414)*, TETRAHEDRON 3557 (1992).
42. Leeson, P. D.; Carling, R. W.; Williams, B.J.; Baker, R.; Ladduwahetty, T.; Moore, K. W.; Rowley, M.; Foster, A. C.; Kemp, J. A., *Non-competitive N-methyl-D-aspartate antagonists; structure-activity relationships for compounds acting at the ion channel and glycine sites*, TRENDS MED. CHEM. '90, 11th PROC. INT. SYMP. MED. CHEM. 169-74 (eds. Shalom Sarel, Raphael Mechoulam, Israel Agranat, (1992).
43. Leeson, P.D.; Carling, R.W.; Williams, B.J.; Baker, R.; Ladduwahetty, T.; Moore, K.W.; Rowley, M.; Foster, A.C.; Kemp, J.A.; Tricklebank, M.D., *Non-competitive n-methyl-D-aspartate antagonists: Structure Activity Relationships for compounds acting at the ion channel and glycine sites*, TRENDS IN MEDICINAL CHEMISTRY '90 169-74 (Blackwell Scientific Publications, ed. S. Sarel, Oxford, 1992).
44. Rowley, M. and Leeson P.D., *Excitatory Amino Acid Antagonists*, 2 CURRENT OPINION IN THERAPEUTIC PATENTS 1201 (1992).
45. Stevenson, G.I.; Leeson, P.D.; Rowley, M.; Sanderson, I.; Stansfield, I, *Synthesis of cis and trans 4-Amido 2-Carboxytetrahydroquinolines, high affinity ligands at the glycine site of the NMDA Receptor*, 2 BIOORG. MED. CHEM. LETT. 371 (1992).

46. Leeson, P.D.; Williams, B.J.; Baker, R.; Ladduwahetty, T.; Moore, K.W.; Rowley, M., *Effects of Five-Membered Ring Conformation on Bioreceptor Recognition: Identification of 3R-Amino-1-Hydroxy-4R-Methylpyrrolidin-2-One (L-687,414) as a Potent Glycine/N-Methyl- D-Aspartate Receptor Antagonist*, J. CHEM. SOC., CHEM. COMMUN. 1578 (1990).
47. Rowley, M.; Masamitsu, T.; Kishi, Y., *Total Synthesis of Ophiobolin C*, 111 J. AM. CHEM. SOC. 2735 (1989).
48. Rowley, M.; Kishi, Y., *Synthetic Studies on Ophiobolins*, TET. LETT. 4909 (1988).
49. Fleming, I.; Rowley, M.; Cuadrado, P.; González-Nogal, A.M.; Pulido, F.J., *The Silyl-Cupration and Stannyl-Cupration of Allenes*, TETRAHEDRON 413 (1989).
50. Fleming, I.; Rowley, M., *A Regiocontrolled Synthesis of Allylstannanes*, J. CHEM. SOC., PERKIN I 2259 (1987).
51. Fleming, I.; Rowley, M., *A Regiocontrolled Synthesis of Allylstannanes*, TET. LETT. 5417 (1986).
52. Fleming, I.; Rowley, M., *The Stereochemistry of the Intramolecular Attack of an Aldehyde on a Carbon-Tin Bond*, TETRAHEDRON 3181 (1986).
53. Fleming, I.; Rowley, M., *The Stereochemistry of Attack by a Carbon Electrophile on a Tin-Carbon Bond*, TET. LETT. 3857 (1985).

Annex B: Representative Patents and Patent Publications

1. Dioxotetrahydroquinolines. EP 0459561 A (1991).
2. Hydroxyquinolone derivatives. EP 0481676 A (1992).
3. 2(1H)-Quinolone Derivatives. WO 9310783 A (1993).
4. 3-Phenyl-2(1H)-quinolone derivatives. WO 9311115 A (1993).
5. (Piperidiny)pyrazoles and Analogs. WO 9410145 A (1994).
6. Dopamine receptor subtype ligands. WO 9410162 A (1994).
7. Pyrimidine derivatives for treatment of dopamine disorders.
WO 9426733 A (1994).
8. Fused tricyclic heteroaromatic derivatives. WO 9507893 A
(1995).
9. Fused tricyclic heteroaromatic derivatives. WO 9507262 A
(1995).
10. Piperazine, piperidine and tetrahydropyridine derivatives.
WO 9718203 (1997).
11. Substituted piperidine derivatives as selective agonists of 5-HT
receptors. WO 9718202 (1997).
12. Indolylalkyl piperazines as selective 5-HT₁ agonists. WO
9719943 (1997).
13. Preparation of heteroarylpyridones as GABAA $\alpha 2/\alpha 3$ ligands. WO
9855480 (1998).
14. Preparation of phenylindoles as 5-HT_{2A} receptor ligands.
WO 9911619 (1999).
15. Preparation of 3-(piperidin-4-yl)-2-phenylindoles as 5-HT_{2A}
receptor antagonists. WO 9911641 (1999).
16. Preparation of 3-(piperidin-3-yl)-1H-indole derivatives as 5-HT_{2A}
receptor antagonists for treatment of psychotic disorders such as schizophrenia.
WO 9947511 (1999).
17. Preparation of triazolopyrimidines as ligands for GABA receptors.
WO 9965907 (1999).

18. Preparation of 3-azabicyclooctyl-2-phenylindoles as selective antagonists of 5-HT_{2A} receptors. WO 0004017 (2000).
19. Preparation of phenylindoles as 5-HT_{2A} receptor ligands. WO 0005229 (2000).
20. Imidazotriazine derivatives as ligands for GABA receptors. WO 0114377(2001).
21. Preparation of imidazopyridines as GABA_A receptor ligands. WO 0118000 (2001).
22. Preparation of 3-phenylimidazo[1,2-a]pyridines as ligands for GABA receptors. WO 0138326 (2001).
23. Preparation of tricyclic pyridin-2-one analogue as a GABA receptor ligand. US 20010053776 (2001).
24. Preparation of tricyclic pyridin-2-one analogues as ligands for GABA_A receptors. WO 2003016311 (2003).
25. Preparation of tricyclic pyridin-2-one analogues as ligands for GABA_A receptors. WO 2003018546 (2003).
26. Preparation of tricyclic pyridin-2-one analogues as GABA_A receptor ligands. WO 2003024964 (2003).
27. Preparation of N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase. WO 2003035077 (2003).
28. Preparation of tetrahydro-4H-pyrido[1,2-a]pyrimidines and related compounds as HIV integrase inhibitors. WO 2004058756(2004).
29. A preparation of tetrahydro-4H-pyrido[1,2-a]pyrimidine derivatives, useful as HIV integrase inhibitors. WO 2004058757 (2004).
30. Preparation of indole acetamides as inhibitors of the hepatitis c virus NS5B polymerase. WO 2004087714 (2004).
31. Thienopyrroles as antiviral agents. WO 2005023819 (2005).
32. Indoles and azaindoles as antiviral agents. WO 2005034941 (2005).
33. Preparation of amino acid amide derivatives as inhibitors of histone deacetylase. WO 2006005941 (2006).

34. Preparation of naphthalimide derivatives as antiviral agents.
WO 2006027628 (2006).
35. Preparation of tetracyclic indole derivatives as antiviral agents for
hepatitis C. WO 2006046039 (2006).
36. Preparation of tetracyclic indole derivatives as antiviral agents.
WO 2006046030 (2006).
37. Preparation of heterocycle derivatives as histone deacetylase
inhibitors. WO 2006061638 (2006).